DSGN
$11.04
Design Therapeutics, Inc.
Intraday
Recent News
Design Therapeutics Maps H2 Data Readouts for RESTORE-FA, FECD Biomarker Study and DM1 Program
Design Therapeutics (NASDAQ:DSGN) outlined its near-term clinical priorities and key upcoming data readouts during a conference discussion with Leerink Partners’ Joe Schwartz, featuring comments from CEO Pratik Shah. The conversation focused on the company’s Friedreich’s ataxia (FA) program, ongoing
Design Therapeutics Highlights GeneTAC Pipeline, FA Data Timeline and DM1 Dosing Plans at Oppenheimer Conference
Design Therapeutics (NASDAQ:DSGN) outlined progress across three clinical-stage programs and discussed upcoming catalysts during an Oppenheimer healthcare conference presentation led by CEO Pratik Shah. The company is developing what it describes as “small molecule genetic medicines” designed to mod
Design Therapeutics' Friedreich Ataxia Program Shows Potential, RBC Says
Design Therapeutics' (DSGN) Friedreich Ataxia program could deliver meaningful clinical benefits and
Here Are Thursday’s Top Wall Street Analyst Research Calls: AON, Apollo Global, Bullish, Jack Henry, Marsh & McClennan, Nasdaq, NVIDIA, and More
Pre-Market Stock Futures: The futures are trading higher after NVIDIA Inc. (NASDAQ: NVDA) blew out its fiscal third-quarter results and offered strong forward guidance, though perhaps not as robust as Wall Street had hoped. Shares were up over 5% after the company reported earnings per share of $1.30, above estimates of $1.25, and revenue of ... Here Are Thursday’s Top Wall Street Analyst Research Calls: AON, Apollo Global, Bullish, Jack Henry, Marsh & McClennan, Nasdaq, NVIDIA, and More
Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...